Introduction
============

Gastrointestinal (GI) symptoms are the most prominent and disabling non-motor manifestations of Parkinson's disease (PD).[@b1-jnm-24-469] Patients with PD patients develop various GI symptoms, including dry mouth, drooling, dysphagia, gastroparesis, and constipation.[@b1-jnm-24-469],[@b2-jnm-24-469] Although the clinical understanding of GI dysfunction in PD patients has increased substantially, the pathophysiological mechanism of GI involvement in PD is still unclear.

α-Synuclein (αSYN) is the main component of Lewy bodies and Lewy neurites, which are the main neuropathological hallmarks of PD.[@b3-jnm-24-469] The abnormal deposition of aggregated αSYN initially occurs in the olfactory bulb and dorsal motor nucleus of the vagus nerve (DMV) in the medulla; thereafter, it spreads through less vulnerable nuclear gray and cortical areas in an ascending course.[@b4-jnm-24-469] Researchers have also found αSYN aggregation in the enteric nervous system (ENS), occurring at the earliest stage of PD, or even preceding the onset of PD.[@b5-jnm-24-469]--[@b7-jnm-24-469] GI symptoms also occur from the earliest stage of PD, and constipation is known to precede the motor symptoms of the disease.[@b1-jnm-24-469],[@b8-jnm-24-469] In addition, the extent of GI dysfunction corresponds with widespread ENS synucleinopathy, suggesting that the abnormal deposition of αSYN in the ENS could be the main cause of GI dysfunction in PD.[@b9-jnm-24-469] However, no studies have shown a causative link between this pathological abnormality and the corresponding GI deficit in PD.[@b2-jnm-24-469]

Several recently published studies have reported that αSYN is also present in the colonic mucosa or submucosa of persons without neurodegenerative diseases.[@b10-jnm-24-469]--[@b12-jnm-24-469] Our group also reported that there was no difference in the αSYN immunoreactivity of gastric and colonic mucosal tissues obtained through routine endoscopy among PD patients and controls.[@b13-jnm-24-469] However, the functional impact of αSYN pathology in the GI tract of neurologically intact persons remains unknown. The role of ENS synucleinopathy in neurologically intact persons in predicting future PD risk has also not been evaluated.

Therefore, in the present study, we aim to evaluate the association between the αSYN pathology in the human GI tract, and GI dysfunction in PD patients and neurologically intact persons, as well as to investigate the association between the αSYN pathology in the GI tract and the subsequent risk of PD in neurologically intact subjects.

Materials and Methods
=====================

Study Population
----------------

Our group's preceding study was a prospective study comparing αSYN immunoreactivity between PD and controls (neurologically intact subjects).[@b13-jnm-24-469] In this study, the sample population comprised of 87 subjects who completed the validated Korean Rome III questionnaire (Rome III-K) among the participants of the preceding study.[@b13-jnm-24-469],[@b14-jnm-24-469] We enrolled PD patients and controls between August 2013 and February 2015. The PD patients were enrolled from the clinical practice of the Department of Neurology at Asan Medical Center, a tertiary university hospital in Seoul, South Korea, and the diagnosis of PD was made by experienced movement disorder specialists by using the clinical diagnostic criteria of the United Kingdom PD Society Brain Bank.[@b15-jnm-24-469] Control subjects older than 45 years, without a history of neurological disorders, and who visited the gastroenterology outpatient clinic at the Asan Medical Center were prospectively enrolled in this research. We screened all of the controls for PD by using the "Nine-symptom screening tool,"[@b16-jnm-24-469] and the subjects were examined by neurologists (S.J.C., J.K., H.S.R., and M.J.K.) to exclude neurological disorders. The control subjects had no psychological diseases, no tremors, and no impairment in cognitive function or the activities of daily living. Subjects were excluded if they had chronic GI diseases, such as Crohn's disease or ulcerative colitis, or if they showed active GI diseases in their esophagogastroduodenoscopy (EGD) or colonoscopy, such as a gastric ulcer, gastritis, colitis, or cancer.

Endoscopic Biopsy
-----------------

The enrolled subjects underwent an EGD, colonoscopy, or both, as recommended by the gastroenterologist in routine clinical practice. An endoscopy was performed by 3 gastroenterologists (H.J.L., K.W.J., and J.H.L.) according to the usual procedure followed by the Gastroenterology Department of Asan Medical Center. We performed gastric mucosal biopsies in the fundus and antrum by using standard biopsy forceps (FB-25K-1; standard fenestrated cups; Olympus, Tokyo, Japan). Colonic mucosal biopsies were also performed in the ascending colon, transverse colon, and sigmoid colon by using standard biopsy forceps (FB-24U-1; standard fenestrated cups with needle, Olympus). Two random biopsies were taken from each biopsy site, and the two biopsies obtained from the same site were considered as a single sample. After sampling, the gastric and colonic mucosal specimens were immediately fixed in 10% formalin.

Our study protocol was approved by the institutional review board of Asan Medical Center (Protocol No. 2013-0175), and informed consent was obtained from all subjects.

Immunohistochemical Staining and Tissue Assessment Procedures
-------------------------------------------------------------

The primary antibodies for αSYN (1:200; EP1536Y; AB-CAM, Cambridge, UK) and S-100 protein (1:200; 18-0046; Zymed, South San Francisco, CA, USA), with BenchMark autostainers (Ventana Medical Systems, Tuscan, AZ, USA), were used according to the manufacturers' protocol. Then, 4-μm tissue sections were deparaffinized, and hydrated in xylene and serially diluted ethanol, respectively. Endogenous peroxidase was blocked by incubation in 3% H~2~O~2~ for 10 minutes, after which heat-induced antigen retrieval was performed for 32 minutes. After primary antibody incubation for 32 minutes at room temperature, detection was carried out with an I-View detection kit (BenchMark XT, Ventana Medical Systems).

The specimens were determined to be adequate for αSYN immunostaining when sufficient numbers of sections were available for analysis, and the density of S-100-positive nerve cells was at least low to moderate, with the presence of the muscularis mucosa. A section with at least one definite αSYN immunoreactive fiber was considered to be positive when compared with the positive control of αSYN immunoreactivity (ie, Lewy body-like inclusions or Lewy neurites from the brain tissues of PD patients; [Fig. A](#f1-jnm-24-469){ref-type="fig"}). The neuropathological findings were assessed by one neuropathologist (S.M.H.) and one experienced neurologist (J.K.) who were blinded to the clinical information of subjects.

Assessment of Gastrointestinal Symptoms
---------------------------------------

All subjects completed the validated Korean Rome III questionnaire to assess their GI symptoms (Rome III-K).[@b14-jnm-24-469] The questionnaires evaluated the frequency and duration of the GI symptoms, including epigastric burning, early satiation, postprandial fullness, epigastric pain, acid reflux, nausea, vomiting, abdominal pain or discomfort, constipation, bloating, and fecal incontinence, during the previous 3 months. Each self-reported GI symptom was defined as "presence" if it met the following criteria set by Rome III[@b17-jnm-24-469]: epigastric burning, epigastric pain, and vomiting one or more times per week; early satiation, postprandial fullness, and nausea from 2 to 3 or more times per week; and abdominal pain or discomfort and bloating for ≥ 3 days/month. The presence of acid reflux was confirmed when the symptom occurred more than once per week, and the presence of fecal incontinence was confirmed when the symptom occurred more than once per month. The presence of self-reported constipation was confirmed when the subjects reported defecatory difficulty. Functional GI disorders (functional dyspepsia, irritable bowel syndrome, and functional constipation) were diagnosed as defined by the Rome III criteria. In the PD patients, the presence of drooling and dysphagia were also assessed by using the non-motor symptom assessment scale for PD.[@b18-jnm-24-469]

We evaluated the association between the presence of GI symptoms and the αSYN pathology of the GI tract in PD patients and neurologically intact subjects. We also assessed the relation between upper GI symptoms and αSYN in the gastric samples, as well as the relation between lower GI symptoms and αSYN in the colon samples. This assessment sought to evaluate the organ-specific association between the αSYN pathology and GI symptoms. Upper GI symptoms included drooling, dysphagia, epigastric burning, early satiation, postprandial fullness, epigastric pain, acid reflux, nausea, and vomiting. Lower GI symptoms included abdominal pain or discomfort, constipation, bloating, and fecal incontinence.

Ascertainment of Parkinson's Disease
------------------------------------

The outcome of interest was defined as having a disease code for expanding benefit coverage for PD patients' (V124) registration with the Korean National Health Insurance Service.

Statistical Methods
-------------------

The differences in the continuous variables between the groups were evaluated by using the Mann--Whitney U test, and the differences in the categorical variables were evaluated with the χ^2^ test or Fisher's exact test. Data were analyzed with SPSS 20.0 (IBM Corp, Armonk, NY, USA), and *P*-values \< 0.05 were considered to be statistically significant.

Results
=======

Baseline Characteristics of the Study Population
------------------------------------------------

A total of 35 PD patients and 52 controls were enrolled in this study, and the baseline characteristics and GI symptoms of the subjects are shown in [Table 1](#t1-jnm-24-469){ref-type="table"}. There were no significant differences between the two groups in terms of age, sex, and body mass index.

Among the 35 PD patients, the median disease duration was 7 years (range, 2--21 years), the mean levodopa equivalent dose was 816 mg/day, the mean Hoehn and Yahr stage was 2.4, and the mean total unified PD rating scale score was 40.9. Three patients (8.6%) underwent EGD only, 16 (45.7%) underwent colonoscopy only, and 16 (45.7%) underwent both procedures.

Among the 52 controls, 21 subjects (40.4%) were given screening endoscopies without GI symptoms. The main reasons for performing endoscopy in the remaining controls (n = 31, 59.6%) were as follows: constipation (n = 18), abdominal pain or discomfort (n = 6), acid reflux (n = 2), epigastric pain (n = 1), postprandial discomfort (n = 1), bloating (n = 1), and diarrhea (n = 2). Seven subjects (13.5%) underwent EGD only, 24 (46.2%) underwent colonoscopy only, and 21 (40.4%) underwent both procedures.

The rates of self-reported constipation and functional constipation through the Rome III questionnaire were significantly higher in PD patients than in controls (*P* \< 0.001 and *P* = 0.015). The other self-reported GI symptoms and functional GI disorders did not differ between the two groups.

α-Synuclein in the Gastric or Colonic Mucosa Is Not Associated With Gastrointestinal Symptoms
---------------------------------------------------------------------------------------------

Of the 87 subjects, 79 (90.8%) had one or more adequate quality samples, and were assessable for neuropathological study; αSYN was documented in 32 subjects (40.5%). αSYN immunostaining in the gastric and colonic endoscopic biopsy tissue were illustrated in [Figure B--E](#f1-jnm-24-469){ref-type="fig"}. There was no difference in the αSYN immunoreactivity between the controls and PD patients (43.5% vs 36.4%, *P* = 0.643; [Supplementary Table 1](#s1-jnm-24-469){ref-type="supplementary-material"}).

The GI symptoms of the subjects according to the αSYN immunostaining in the mucosal biopsies, regardless of the presence or absence of an underlying neurological disorder, are indicated in [Table 2](#t2-jnm-24-469){ref-type="table"}. No statistically significant differences were found in the demographic variables, self-reported GI symptoms, or functional GI disorders in Rome III between the negative αSYN group (n = 47) and the positive αSYN group (n = 32). In addition, αSYN positivity in gastric mucosal biopsy was not associated with any upper or lower GI symptoms ([Supplementary Table 2](#s1-jnm-24-469){ref-type="supplementary-material"}), and the results according to the αSYN positivity in the colonic mucosal biopsy were the same ([Supplementary Table 3](#s1-jnm-24-469){ref-type="supplementary-material"}). Moreover, the detailed constipation symptoms did not differ between the two groups ([Supplementary Table 4](#s1-jnm-24-469){ref-type="supplementary-material"}).

The GI symptoms of PD patients according to αSYN immunostaining in the mucosal biopsy are indicated in [Table 3](#t3-jnm-24-469){ref-type="table"}. Among the PD patients, 33 (94.3%) were assessable for neuropathological study, and αSYN was documented in 12 (36.4%) patients. More PD patients with negative αSYN had self-reported constipation than those with positive αSYN (100% vs 75%, *P* = 0.040), whereas functional constipation according to the Rome III criteria did not differ between the two groups. The other self-reported GI symptoms and functional GI disorders did not differ between the two groups.

The GI symptoms of the neurologically intact subjects, according to the αSYN immunostaining in the mucosal biopsy, are indicated in [Table 4](#t4-jnm-24-469){ref-type="table"}. No statistically significant differences were found in the demographic variables, self-reported GI symptoms, or functional GI disorders in Rome III between the negative αSYN group (n = 26) and the positive αSYN group (n = 20).

The Association Between α-Synuclein Pathology in the Gastrointestinal Tract and Future Parkinson's Disease Risk During Short-term Follow-up Was Not Assessed
------------------------------------------------------------------------------------------------------------------------------------------------------------

No incident PD cases were diagnosed during a median follow up of 46 months (range 31--52) among 52 baseline neurologically intact subjects, irrespective of their GI αSYN pathology. The association between the αSYN pathology in the GI tract and future PD risk could not be evaluated.

Discussion
==========

Our present study described the association between the αSYN pathology in the human GI mucosa, and GI dysfunction in PD patients and neurologically intact subjects. The αSYN pathology in the stomach and colon mucosa appeared not to be associated with GI dysfunction. Therefore, our findings suggested that the deposition of αSYN in the stomach and colon mucosal nerve fiber may not be reflected by the functional impairment of the affected segment of the gut, regardless of the presence or absence of clinical PD.

GI dysfunction is the most prominent and disabling non-motor manifestation of PD, and it is significantly more prevalent in PD patients than in controls.[@b1-jnm-24-469] However, the current treatment strategy for GI dysfunction in PD patients has focused on symptomatic treatment.[@b2-jnm-24-469],[@b19-jnm-24-469] An understanding of the pathophysiological mechanism of GI motility dysfunction in PD would help in the development of target treatments for GI symptoms. However, the pathophysiological mechanism is still poorly understood, and even the clinical-pathological correlations between the GI symptoms and PD pathology have not been well evaluated.

The normal function of the GI tract is controlled by intrinsic and extrinsic innervation; intrinsic innervation relies on the ENS, and extrinsic innervation depends on the preganglionic parasympathetic and sympathetic outputs.[@b20-jnm-24-469],[@b21-jnm-24-469] The parasympathetic output originates in the DMV of the medulla and in the sacral parasympathetic nucleus of the spinal cord.[@b20-jnm-24-469],[@b21-jnm-24-469] The ENS is especially thought to play a major role in GI dysfunction in PD.[@b9-jnm-24-469] The ENS has essential roles in controlling bowel movement and secretion, largely independently of influences from the central nervous system, and the widespread distribution of αSYN pathology in the ENS seems to be associated with various symptoms throughout the entire GI tract.[@b9-jnm-24-469],[@b21-jnm-24-469] One clinical study reported a positive correlation between the amount of Lewy neurites in the submucosal plexus of the ENS and the severity of constipation in PD patients, suggesting a pathogenic role for ENS synucleinopathy in GI dysfunction in PD.[@b22-jnm-24-469] However, no neuronal loss in the myenteric plexus in PD was reported, and the rostrocaudal distribution of the αSYN burden in the ENS did not coincide with the characteristics of GI dysfunction in PD, in which constipation is the most frequently occurring symptom, developing in the early phase.[@b1-jnm-24-469],[@b23-jnm-24-469],[@b24-jnm-24-469] Therefore, further evaluation is required concerning the clinical-pathological correlations between ENS synucleinopathy and GI dysfunction in PD, and the possible mechanisms.

Furthermore, recent studies have reported that αSYN was detected in the ENS of neurologically intact subjects; that is, it may not be a specific finding of PD patients.[@b10-jnm-24-469]--[@b12-jnm-24-469],[@b25-jnm-24-469] Our group also reported that the αSYN positivity in the gastric and colonic mucosal biopsied samples was comparable between 38 PD patients and 53 controls (33.3% for the stomach and 18.5% for the colon in the controls).[@b13-jnm-24-469] These studies have raised concerns about whether the αSYN neuropathology is the main pathophysiology of GI dysfunction in PD patients. Moreover, it is not clear what is the role of αSYN in the GI tract of neurologically intact subjects.

To our knowledge, this study is the first to describe the association between the αSYN pathology in the GI tract (upper and lower) of living humans, and comprehensive GI dysfunction in both PD and neurologically intact subjects. In this study, both controls (with or without GI symptoms) and PD patients were enrolled, and the validated and structured Korean Rome III questionnaire (Rome III-K) was used to assess the GI symptoms systematically.[@b14-jnm-24-469] Unfortunately, we could not find any significant association between the αSYN pathology in the GI mucosa and GI dysfunction. One unexpected finding was that PD patients without αSYN had higher rates of self-reported constipation than those with αSYN, which might be an incidental finding due to the low sample size of PD patients.

We postulate several reasons for the negative results of this study. First, the accumulation of αSYN in the ENS may not be the primary cause of the GI dysfunction in PD. The αSYN neuropathology affected not only the ENS but also the DMV, sacral parasympathetic neurons, and sympathetic preganglionic and ganglion neurons; therefore, the contribution of these factors to GI dysfunction in PD remains to be defined.[@b1-jnm-24-469],[@b26-jnm-24-469],[@b27-jnm-24-469] In particular, the DMV is almost affected in PD, and neuronal loss in this nucleus has also been reported.[@b4-jnm-24-469],[@b28-jnm-24-469] The vagal innervation from the DMV is more heavily distributed in the esophagus and stomach than in the distal GI tract; therefore, the dysmotility of the esophagus and stomach is likely to be associated with the involvement of the DMV.[@b4-jnm-24-469],[@b9-jnm-24-469],[@b29-jnm-24-469] Further studies to evaluate the contribution of other affected nervous system components to GI dysfunction are required. In addition, aging, mobility, and drugs used to treat the motor symptoms of PD are also considered to be factors related to GI dysfunction in PD.[@b9-jnm-24-469],[@b30-jnm-24-469] Second, pathological αSYN distinct from physiological αSYN might exist, and the immunohistochemical method used in our study may fail to distinguish between the 2 types. Böttner et al[@b10-jnm-24-469] reported the presence of native αSYN in surgical specimens of the colon in 13 subjects without neurodegenerative diseases, and they suggested that αSYN in the ENS appears to be a normal finding and not an indicator of neurodegenerative processes. One recent interesting study demonstrated that distinct αSYN strains display differential seeding capacities, inducing strain-specific pathologies and neurotoxic phenotypes.[@b31-jnm-24-469] The authors reported that fibrils seem to be the major toxic strain, resulting in progressive motor impairment and cell death. Therefore, further studies are warranted to elaborate on the pathological αSYN characteristics and their functional impact on GI dysfunction. Finally, it is possible that GI dysmotility might be present even in the absence of symptoms.

Another aspect of identifying the role of αSYN pathology in the GI tract of neurologically intact patients was the possibility that GI αSYN pathology could predict PD risk prior to any motor signs of PD. Our study sought to prospectively investigate the association between the αSYN pathology in the GI tract and the subsequent risk of PD in neurologically intact subjects. However, because no incident PD cases were observed in our study period, the assessment could not be done. Although previous studies have reported that αSYN positivity in the GI tissues were obtained several years (2--20 years) prior to the onset of motor symptoms in PD patients, there have been neither large population-based nor prospective cohort studies conducted.[@b6-jnm-24-469],[@b32-jnm-24-469],[@b33-jnm-24-469] Our results were difficult to conclude because of the short follow-up period; therefore, further follow up with our cohort is required.

Our study has the following limitations. First, we did not evaluate the deep layer of the GI tract, including the submucosal and myenteric plexus of the ENS, because we obtained the GI mucosal layer by using endoscopic biopsy forceps. This sampling method was intended to obtain enteric tissues in the living human efficiently, and its usefulness has been reported in the detection of enteric αSYN in PD patients.[@b34-jnm-24-469]--[@b36-jnm-24-469] The low quality of the samples obtained with endoscopic biopsy is also one of the limitations of this study, and this may have affected the results of the neuropathological analysis. Future studies to evaluate the αSYN pathology in the submucosal and myenteric plexus in living humans, by using novel neuropathological methods, are needed. Second, the number of subjects with certain GI symptoms was low, and the severity of symptoms was not assessed.

In conclusion, our present study suggests that the deposition of αSYN in the mucosal ENS may not be reflected by functional impairment of the affected segment of the gut. These data provide a background for further analyses of the αSYN neuropathology and GI dysfunction. Further investigations are warranted to elucidate the pathological αSYN strains in the ENS that are distinguishable from the physiological αSYN strains, as well as their clinical implications, and the exact mechanism of GI motility dysfunction.
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![α-Synuclein (αSYN) immunostaining. (A) Positive control of αSYN immunoreactivity in this study; Lewy body-like inclusions and Lewy neurites with strong αSYN immunoreactivity in brain tissue from autopsy of a patient with Parkinson's disease. (B--E) αSYN immunostaining in gastric and colonic endoscopic biopsy tissues. (B) Gastric tissue from a 78-year-old man with an 11-year history of Parkinson's disease. (C) Colonic tissue from a 55-year-old woman with a 2-year history of Parkinson's disease (D) Gastric tissue from a 67-year-old woman as a control. (E) Colonic tissue from an 80-year-old man as a control. Note the positive αSYN immunoreactivity reveals multiple dots-like or short-linear appearance (arrows), which is located close to the muscularis mucosa (all figures, original magnification, × 200).](jnm-24-469f1){#f1-jnm-24-469}

###### 

Baseline Characteristics and Gastrointestinal Symptoms of the Study Subjects

  Variables                                       Control (n = 52)   PD (n = 35)   *P*-value
  ----------------------------------------------- ------------------ ------------- -----------
  Age (median \[range\], yr)                      63 (50--80)        67 (50--79)   0.098
  Sex (male, n)                                   26 (50.0%)         15 (42.9%)    0.513
  Body mass index (median \[range\], kg/m^2^)     24 (18--34)        22 (17--35)   0.090
  Characteristics of PD                                                            
   Duration of disease (median \[range\], yr)     \-                 7 (2--21)     
   Levodopa equivalent dose (mean ± SD, mg/day)   \-                 816 ± 339     
   Hoehn and Yahr stage (mean ± SD)               \-                 2.4 ± 0.6     
   UPDRS of PD (mean ± SD)                                                         
    Part I                                        \-                 2.9 ± 2.3     
    Part II                                       \-                 11.8 ± 5.6    
    Part III                                      \-                 23.2 ± 9.5    
    Part IV                                       \-                 3.1 ± 2.9     
    Total                                         \-                 40.9 ± 16.8   
  Self-reported GI symptoms (n)                                                    
   Epigastric burning                             5 (9.6%)           2 (5.7%)      0.697
   Early satiation                                9 (17.3%)          3 (8.6%)      0.347
   Postprandial fullness                          10 (19.2%)         2 (5.7%)      0.112
   Epigastric pain                                6 (11.5%)          3 (8.6%)      0.735
   Acid reflux                                    6 (11.5%)          1 (2.9%)      0.234
   Nausea                                         1 (1.9%)           2 (5.7%)      0.562
   Vomiting                                       0 (0.0%)           1 (2.9%)      0.402
   Abdominal pain/discomfort                      13 (25.0%)         3 (8.6%)      0.088
   Constipation                                   24 (46.2%)         32 (91.4%)    \< 0.001
   Bloating                                       14 (26.9%)         6 (17.1%)     0.288
   Fecal incontinence                             3 (5.8%)           2 (5.7%)      1.000
  Functional GI disorder (Rome III) (n)                                            
   Functional dyspepsia                           12 (23.1%)         5 (14.3%)     0.412
   Irritable bowel syndrome                       6 (11.5%)          1 (2.9%)      0.234
   Functional constipation                        25 (48.1%)         26 (74.3%)    0.015

PD, Parkinson's disease; SD, standard deviation; UPDRS, unified Parkinson's disease rating scale; GI, gastrointestinal.

###### 

Gastrointestinal Symptoms of Subjects With Positive and Negative α-Synuclein Immunostaining in the Stomach and Colon Mucosal Biopsies

  Variables                                     Negative (n = 47)   Positive[a](#tfn2-jnm-24-469){ref-type="table-fn"} (n = 32)   *P*-value[b](#tfn3-jnm-24-469){ref-type="table-fn"}
  --------------------------------------------- ------------------- ------------------------------------------------------------- -----------------------------------------------------
  Age (median \[range\], yr)                    65 (50--77)         66 (50--80)                                                   0.301
  Sex (male, n)                                 25 (53.2%)          17 (53.1%)                                                    0.995
  Body mass index (median \[range\], kg/m^2^)   23 (17--35)         24 (18--29)                                                   0.830
  Self-reported GI symptoms (n)                                                                                                   
   Epigastric burning                           1 (2.1%)            4 (12.5%)                                                     0.152
   Early satiation                              5 (10.6%)           5 (15.6%)                                                     0.515
   Postprandial fullness                        7 (14.9%)           4 (12.5%)                                                     1.000
   Epigastric pain                              2 (4.3%)            4 (12.5%)                                                     0.216
   Acid reflux                                  3 (6.4%)            3 (9.4%)                                                      0.682
   Nausea                                       1 (2.1%)            2 (6.3%)                                                      0.563
   Vomiting                                     0 (0.0%)            1 (3.1%)                                                      0.405
   Abdominal pain/discomfort                    6 (12.8%)           7 (21.9%)                                                     0.358
   Constipation                                 35 (74.5%)          17 (53.1%)                                                    0.058
   Bloating                                     12 (25.5%)          6 (18.8%)                                                     0.589
   Fecal incontinence                           2 (4.3%)            3 (9.4%)                                                      0.390
  Functional GI disorder (Rome III) (n)                                                                                           
   Functional dyspepsia                         8 (17.0%)           5 (15.6%)                                                     1.000
   Irritable bowel syndrome                     3 (6.4%)            2 (6.3%)                                                      1.000
   Functional constipation                      28 (59.6%)          20 (62.5%)                                                    0.819

Positive: α-synuclein stain (+) ≥ 1 site.

Eight subjects without adequate samples were excluded from this analysis.

GI, gastrointestinal.

###### 

Gastrointestinal Symptoms of Patients With Parkinson's Disease With Positive and Negative α-Synuclein Immunostaining in the Stomach and Colon Mucosal Biopsies

  Variables                                     Negative (n = 21)   Positive[a](#tfn5-jnm-24-469){ref-type="table-fn"} (n = 12)   *P*-value[b](#tfn6-jnm-24-469){ref-type="table-fn"}
  --------------------------------------------- ------------------- ------------------------------------------------------------- -----------------------------------------------------
  Age (median \[range\], yr)                    67 (51--77)         66 (50--79)                                                   0.567
  Sex (male, n)                                 12 (57.1%)          7 (58.3%)                                                     1.000
  Body mass index (median \[range\], kg/m^2^)   22 (17--35)         22 (18--26)                                                   0.645
  Self-reported GI symptoms (n)                                                                                                   
   Drooling                                     7 (35.0%)           3 (25.0%)                                                     0.703
   Dysphagia                                    3 (15.0%)           1 (8.3%)                                                      1.000
   Epigastric burning                           0 (0.0%)            2 (16.7%)                                                     0.125
   Early satiation                              2 (9.5%)            1 (8.3%)                                                      1.000
   Postprandial fullness                        1 (4.8%)            1 (8.3%)                                                      1.000
   Epigastric pain                              0 (0.0%)            2 (16.7%)                                                     0.125
   Acid reflux                                  0 (0.0%)            1 (8.3%)                                                      0.364
   Nausea                                       0 (0.0%)            2 (16.7%)                                                     0.125
   Vomiting                                     0 (0.0%)            1 (8.3%)                                                      0.364
   Abdominal pain/discomfort                    2 (9.5%)            1 (8.3%)                                                      1.000
   Constipation                                 21 (100.0%)         9 (75.0%)                                                     0.040
   Bloating                                     3 (14.3%)           2 (16.7%)                                                     1.000
   Fecal incontinence                           1 (4.8%)            1 (8.3%)                                                      1.000
  Functional GI disorder (Rome III) (n)                                                                                           
   Functional dyspepsia                         2 (9.5%)            2 (16.7%)                                                     0.610
   Irritable bowel syndrome                     1 (4.8%)            0 (0.0%)                                                      1.000
   Functional constipation                      15 (71.4%)          9 (75.0%)                                                     1.000

Positive: α-synuclein stain (+) ≥ 1 site.

Two Parkinson's disease patients without adequate samples were excluded from this analysis.

GI, gastrointestinal.

###### 

Gastrointestinal Symptoms of Neurologically Intact Subjects With Positive and Negative α-Synuclein Immunostaining in the Stomach and Colon Mucosal Biopsies

  Variables                                     Negative (n = 26)   Positive[a](#tfn8-jnm-24-469){ref-type="table-fn"} (n = 20)   *P*-value[b](#tfn9-jnm-24-469){ref-type="table-fn"}
  --------------------------------------------- ------------------- ------------------------------------------------------------- -----------------------------------------------------
  Age (median \[range\], yr)                    62 (50--76)         66 (51--80)                                                   0.276
  Sex (male, n)                                 13 (50.0%)          10 (50.0%)                                                    1.000
  Body mass index (median \[range\], kg/m^2^)   23 (18--34)         25 (20--29)                                                   0.485
  Self-reported GI symptoms (n)                                                                                                   
   Epigastric burning                           1 (3.8%)            2 (10.0%)                                                     0.572
   Early satiation                              3 (11.5%)           4 (20.0%)                                                     0.682
   Postprandial fullness                        6 (23.1%)           3 (15.0%)                                                     0.711
   Epigastric pain                              2 (7.7%)            2 (10.0%)                                                     1.000
   Acid reflux                                  3 (11.5%)           2 (10.0%)                                                     1.000
   Nausea                                       1 (3.8%)            0 (0.0%)                                                      1.000
   Vomiting                                     0 (0.0%)            0 (0.0%)                                                      N/A
   Abdominal pain/discomfort                    4 (15.4%)           6 (30.0%)                                                     0.292
   Constipation                                 14 (53.8%)          8 (40.0%)                                                     
   Bloating                                     9 (34.6%)           4 (20.0%)                                                     0.336
   Fecal incontinence                           1 (3.8%)            2 (10.0%)                                                     0.572
  Functional GI disorder (Rome III) (n)                                                                                           
   Functional dyspepsia                         6 (23.1%)           3 (15.0%)                                                     0.711
   Irritable bowel syndrome                     2 (7.7%)            2 (10.0%)                                                     1.000
   Functional constipation                      13 (50.0%)          11 (55.0%)                                                    0.774

Positive: α-synuclein stain (+) ≥ 1 site.

Six neurologically intact subjects without adequate samples were excluded from this analysis.

GI, gastrointestinal.
